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Abstract
In this case report, we describe for the first time a patient
with thrombotic thrombocytopaenic purpura (TTP) accom-
panying highly active systemic lupus erythematosus (SLE)
that was associated with non-neutralizing antibodies
against the plasma metalloprotease ADAMTS13. Those
non-neutralizing antibodies could have been the cause of
ADAMTS13 depletion and consecutive TTP. More exten-
sive analyses are required to determine the prevalence as
well as the clinical relevance of non-neutralizing antibo-
dies against ADAMTS13 in SLE patients.
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Introduction
Thrombotic thrombocytopaenic purpura (TTP) is a life-
threatening syndrome of acute mechanical haemolytic
anaemia, thrombocytopaenia and visceral ischaemic man-
ifestations related to the formation of platelet thrombi in
the microcirculation [1]. TTP can be of congenital or ac-
quired origin with TTP occurring in the context of predis-
posing conditions such as stem cell transplantation or
treatment with calcineurin inhibitors being considered as
‘secondary’. Recent research suggests that the functional
deficiency of von Willebrand factor-cleaving protease
ADAMTS13 (a disintegrin-like and metalloprotease with
thrombospondin type 1 repeats), either congenital due to
genomic mutations or acquired due to autoantibodies di-
rected against ADAMTS13, plays an important role in
the pathogenesis of primary TTP. The lack of ADAMTS13
may lead to the accumulation of unusually large von Will-
ebrand factor (ULVWF) multimers, platelet clumping and
thrombotic occlusions within the microvasculature [2,3].
Secondary TTP accompanying systemic lupus erythe-
matosus (SLE) has been well reported in the literature
but the pathogenic mechanism that accounts for their co-
existence is incompletely understood. In SLE patients,
TTP seems to be of autoimmune, i.e. acquired nature be-
cause low levels of ADAMTS13 were usually associated
with the presence of autoantibodies that inhibit the enzyme
activity [1,3]. However, more recently, non-neutralizing
antibodies, i.e. anti-ADAMTS13 immunoglobulin G
(IgG) and/or IgM antibodies associated with normal
ADAMTS13 activity, have been detected in 13–18% of
SLE patients using an enzyme-linked immunosorbent as-
say (ELISA) [4] suggesting an additional mechanism for
acquired ADAMTS13 deficiency in SLE [4,5]. However,
the significance of this observation, i.e. non-neutralizing
IgG anti-ADAMTS13 antibodies in SLE patients, remains
to be determined. Here, for the first time, we describe a
patient in whom active SLE and active TTP occur simul-
taneously, with severely reduced ADAMTS13 activity and
in the presence of non-neutralizing anti-ADAMTS13 IgG
antibodies.
Case report
In January 2007, a 20-year-old female patient was admit-
ted to our hospital. She reported shortness of breath
and increase in body weight from 84 to 103 kg within
2 weeks. Two weeks before, the patient suffered from an
upper respiratory tract infection with fatigue, malaise and
rhinitis, which was treated symptomatically. On admis-
sion, she was afebrile, and her blood pressure was 160/
115 mm Hg with a pulse rate of 120/min. She presented
a malar rash and anasarca. The patient also reported
blurry vision of the left eye, which normalized before
being confirmed by an ophthalmologist. No further focal
neurological deficits could be found. Apart from reduced
pulmonary respiratory sounds, lung and heart examina-
tion was normal.
A chest X-ray revealed cardiomegaly and bilateral pleu-
ral effusions. The trans-thoracic echocardiogram showed a
pericardial effusion and global hypokinesia with a left ven-
tricular ejection fraction of 45%.
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Blood tests showed haemolytic anaemia with a haemo-
globin of 60 g/L; total bilirubin was 30 umol/L (norm:
5–18 μmol/L), and lactate dehydrogenase was 774 U/L
(norm: 135–214 U/L). Peripheral blood smear revealed
5 to 10 schistocytes per visual field. The platelet count
was decreased to 17 × 109/L (norm: 150–450 × 109/L).
On admission, serum creatinine was 214 umol/L (norm:
45–93 umol/L), and urinalysis revealed >50 dysmorphic
and non-dysmorphic erythrocytes and one to two leuco-
cytes per high-power field. The urine protein/creatinine
ratio was 276 mg/mmol (norm <11 mg/mmol). Two days
after admission, haemodialysis had to be started due to
anuric renal failure.
A direct antiglobulin (Coombs) test was weakly positive
for IgG. In addition, the patient had an antinuclear anti-
body (ANA) titer positive at 1:1280 (norm: <1:80) and
antibodies against double-stranded DNA (727 IU/ml, Farr
assay, norm: <7 U/ml). Complement C3 and C4 levels
were low at 14 (norm: 50–90 mg/dl) and 2.7 mg/dl (norm:
10–40 mg/dl), respectively. No antibodies against cardioli-
pin (IgG and IgM) could be detected.
A renal biopsy showed a diffuse proliferative glomer-
ulonephritis (GN) with characteristics of an endocapil-
lary as well as a membranoproliferative GN. The
glomeruli showed a number of mesangiolytic lesions
and intravascular protein thrombi. In addition, renal in-
farction with acute tubular necrosis of unknown origin
could be observed in some areas. Immunofluorescence
was positive for IgG, IgM and IgA as well as for com-
plement C1q, C4, C3 and C5b-9. Electron microscopy
showed subendothelial deposits with finger print-like
structures. The findings were compatible with severe
type IV lupus nephritis but were not typical of throm-
botic microangiopathy.
In a magnetic resonance imaging of the neurocranium,
small vessels had a pearl cord-like appearance with ischae-
mias in the right cerebellum and the right frontal cortex.
Radiologically, the findings were considered to be compat-
ible with cerebral vasculitis.
Based on the initial findings, the diagnosis of SLE was
established. In addition, due to features of thrombotic mi-
croangiopathy, ADAMTS13 activity was determined. Se-
verely reduced ADAMTS13 activity (<5%) and antigen
levels (0.130 μg/ml, normal antigen range 0.740–1.420
μg/ml) were found but no inhibitory anti-ADAMTS13
antibodies. Since the coincidence of SLE with hereditary
ADAMTS13 deficiency appeared unlikely, further blood
tests were initiated. Using an ELISA-based method, low
levels of IgG anti-ADAMTS13 antibodies (titer 1/50)
binding to ADAMTS13, but not inhibiting its function in
vitro, were found. IgM and IgA anti-ADAMTS13 antibo-
dies were negative. Subclass characterization of the IgG
anti-ADAMTS13 antibodies showed a prevalence of
IgG1 (89%) and very low levels of IgG3 (4%) and IgG2
(7%) antibodies. No IgG4 anti-ADAMTS13 antibodies
could be detected.
Immunosuppression consisting of high-dose prednisone
(methylprednisolone 1 g/day for 3 days followed by pred-
nisone 150 mg/day, tapered during the following weeks)
and cyclophosphamide pulses (500 mg every 2 weeks
for 3 months, i.e. six doses) as well as daily plasma ex-
change (PEx) were started (3.5 L plasma were exchanged
with fresh frozen plasma). In addition, due to the severe
systemic involvement of SLE, anti-CD20 antibodies
(rituximab) were given (two doses of 1 g administered
2 weeks apart). With this combined treatment, improve-
ment of renal function, haemoglobin levels, platelet counts
and normalization of ADAMTS13 activity were achieved.
Haemodialysis could be stopped after 10 days. PEx was
tapered and could be ceased after a total of 18 proce-
dures. The patient became asymptomatic and could be
discharged 5 weeks after admission. Under a maintenance
therapy with mycophenolate and hydroxychloroquine, the
patient remained asymptomatic. Upon last follow-up,
22 months later, serum creatinine was 69 μmol/L.
Methods
Determination of ADAMTS13 activity, ADAMTS13 antigen and
ADAMTS13 inhibitors
ADAMTS13 activity and inhibitor determination were performed as
described [4,6]. ADAMTS13 antigen levels were analysed by an ELISA
according to Rieger et al. [6]. Briefly, a purified polyclonal rabbit anti-
human ADAMTS13 IgG fraction was used for both the capture and the
detection step of human plasmatic ADAMTS13 (reference interval:
0.740–1.420 μg/mL). The intra- and inter-assay coefficients of variation
(%CV) were found to be 2.5% and 11.1%, respectively.
Determination of anti-ADAMTS13 antibodies
Total IgG, IgG subclasses, IgM and IgA anti-ADAMTS13 antibodies
were analysed by ELISA as described [4,7,8]. The ELISA uses an anti-
His tag antibody to capture recombinant His-tagged ADAMTS13. Diluted
plasma samples are added, and bound total IgG, IgM, IgA or IgG sub-
classes are detected using an alkaline phosphatase-conjugated goat anti-
human IgG, IgM or IgA antibody (Sigma, St. Louis, MO, USA) or mouse
monoclonal anti-human IgG1, IgG2, IgG3 and IgG4 antibodies (Zymed
Laboratories, San Francisco, CA, USA). The results are expressed either
as a titer (total IgG, IgM or IgA) or as percentage (IgG subclasses). The
inter-assay CV of the ELISA was found to be <20%.
Discussion
Deficiency of von Willebrand factor-cleaving protease
ADAMTS13 was reported to be a specific finding of acute
TTP [9]. Frequently, the acquired form of ADAMTS13
deficiency is associated with the presence of circulating
autoantibodies (inhibitors) that neutralize ADAMTS13 ac-
tivity [2,3,10]. However, in our patient with SLE-associated
TTP, the severe reduction in ADAMTS13 activity was not
associated with neutralizing anti-ADAMTS13 antibodies
but with the presence of non-neutralizing antibodies that
were missed by the functional inhibitor assay. These non-
neutralizing antibodies were detected by a newly developed
ELISA method where they bind to immobilized recombi-
nant ADAMTS13.
Considering the very low levels of ADAMTS13 on ad-
mission, the severe thrombocytopaenia and the haemolytic
anaemia that was not fully explained by the weakly posi-
tive Coombs test, the non-neutralizing anti-ADAMTS13
antibodies observed in our patient are likely to be of clin-
ical relevance. However, we did not observe thrombotic
microangiopathy in the kidney biopsy, and no definite neu-
rological abnormality could be detected. Thus, more stud-
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ies will be required to clarify the potential pathogenic role
of non-neutralizing anti-ADAMTS13 antibodies.
Recent reports could also demonstrate the presence of
non-neutralizing antibodies in a patient with TTP and in
patients with SLE without TTP [4,5], suggesting that me-
chanisms other than the direct inhibition of protease activ-
ity of ADAMTS13 by autoantibodies may be involved in
TTP. One explanation could be that non-neutralizing anti-
bodies bind to regions of ADAMTS13 which are not nec-
essary for exerting protease activity under the conditions
of the in vitro assay. In vivo, however, they could lead to
an increased clearance of the ADAMTS13–antibody com-
plexes and/or interfere with shear stress-dependent cleav-
age of ULVWF by ADAMTS13.
In conclusion, for the first time, we report a patient
with TTP accompanying highly active SLE that was
associated with non-neutralizing antibodies against
ADAMTS13. Those non-neutralizing anti-bodies could
have been the cause of ADAMTS13 depletion and consec-
utive TTP. More extensive analyses are required to deter-
mine the prevalence as well as the clinical relevance of
non-neutralizing antibodies against ADAMTS13 in SLE
patients.
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